Dario Vignali, PhD, on Immune Resistance Mechanisms in Cancer
2020 ASCO-SITC Clinical Immuno-Oncology SymposiumDario Vignali, PhD, of the University of Pittsburgh and UPMC Hillman Cancer Center, summarizes his Keynote Address, which covered what drives systemic immune dysfunction in patients with cancer, what promotes inhibitory receptor expression, and what limits the persistence of antigen-specific T cells.
Related Videos
Kevin Tyan on Colitis Induced by Immune Checkpoint Inhibitors: Potential Preventive Strategy
Kevin Tyan, of Kinnos, and currently a medical school student at Harvard University, discusses his study findings, which showed that patients with melanoma who are treated wi...
Jarrett Failing, MD, on Human Leukocyte Antigen Expression in NSCLC With Brain Metastases
Jarrett Failing, MD, of the Mayo Clinic, discusses his study data, which show some agreement between the expression of human leukocyte antigens in primary non–small cell lung...
Christopher B. Cole, MD, PhD, on Ovarian Cancer: First-in-Human Study of Interferon-Activated Autologous Monocytes
Christopher B. Cole, MD, PhD, of the National Cancer Institute, discusses findings from a phase I study of intraperitoneal monocytes activated by interferons alpha and gamma ...
Elizabeth A. Mittendorf, MD, PhD, on Mobilizing the Immune System to Treat Select Solid Tumors
Elizabeth A. Mittendorf, MD, PhD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, summarizes a session she co-chaired on utilizing the immune system in neoa...
Philippa G. Corrie, PhD, on Patient Outcomes in Melanoma After Immune Checkpoint Inhibition
Philippa G. Corrie, PhD, of Cambridge University Hospitals NHS Foundation Trust, discusses a review of 2,322 patients with metastatic melanoma receiving first-line immune che...
